Olaparib as a maintenance therapy in newly diagnosed patients with ovarian cancer - SOLO1 study results
2022
Abstract
The ovarian cancer has been a disease with an uncertain prognosis and a high mortality for a long time. The importance of poly(ADP-ribose) polymerase (PARP) inhibition in its treatment was clearly proved.
The SOLO1 study in a newly diagnosed advanced ovarian cancer demonstrates the benefit of olaparib as a maintenance treatment, significantly improving progression free survival with a good quality of life for patients.